Ancient Classical Prescriptions Treating Middle and Advanced Primary Liver Cancer:A Meta-analysis of Randomized Controlled Trials
10.3969/j.issn.1005-5304.2015.11.009
- VernacularTitle:古方治疗中晚期原发性肝癌随机对照试验Meta分析
- Author:
Xiuxiu ZHAO
;
Bo LI
;
Qian QU
;
Teng HAO
;
Weili LIU
;
Yu WU
- Publication Type:Journal Article
- Keywords:
ancient classical prescriptions;
symptomatic therapy;
middle and advanced primary liver cancer;
randomized controlled trial;
Meta-analysis
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2015;22(11):31-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of ancient classical prescriptions treating middle and advanced primary liver cancer.Methods Articles were searched from Pubmed, Embase, SCI, Cochrane Liarary and CNKI, VIP, WanFang Data, CBM databases. Randomized controlled trials about ancient classical prescriptions treating advanced primary liver cancer were collected. Results 17 studies were included, a total of 994 patients. The recent efficiency of ancient classical prescription combined with symptomatic therapy increased by 28% compared with single supportive and symptomatic therapy;the stable rate of life quality increased by 23%;the efficiency of TCM syndrome increased by 29%;the survival rates of 3 months, 6 months and 1 year increased by 16%, 36.7% and 58.5% respectively;the life quality score of later increased by 6.29 on average. Conclusion Ancient classical prescription combined with supportive and symptomatic therapy in advanced primary liver cancers is superior to single supportive and symptomatic therapy on recent efficiency, survival rate (3 months/6 months/1 year), quality of life and TCM syndrome. The conclusion of this study needs randomized controlled trials with larger samples, multicenter and high quality for further verification.
